Singapore markets closed

Galera Therapeutics, Inc. (GRTX)

NasdaqGM - NasdaqGM Delayed price. Currency in USD
Add to watchlist
0.1898+0.0035 (+1.88%)
At close: 04:00PM EDT
0.1897 -0.00 (-0.05%)
Pre-market: 08:36AM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 10.32M
Enterprise value -6.68M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)29.39
Enterprise value/revenue N/A
Enterprise value/EBITDA 0.14

Trading information

Stock price history

Beta (5Y monthly) 2.17
52-week change 3-93.79%
S&P500 52-week change 323.57%
52-week high 33.5900
52-week low 30.0850
50-day moving average 30.1988
200-day moving average 30.3761

Share statistics

Avg vol (3-month) 32.07M
Avg vol (10-day) 31.12M
Shares outstanding 554.39M
Implied shares outstanding 654.39M
Float 841.94M
% held by insiders 125.20%
% held by institutions 119.46%
Shares short (15 Apr 2024) 42.66M
Short ratio (15 Apr 2024) 41.29
Short % of float (15 Apr 2024) 46.61%
Short % of shares outstanding (15 Apr 2024) 44.89%
Shares short (prior month 15 Mar 2024) 42.8M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-83.63%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -46.69M
Net income avi to common (ttm)-59.08M
Diluted EPS (ttm)-1.3300
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)18.26M
Total cash per share (mrq)0.34
Total debt (mrq)152.3M
Total debt/equity (mrq)N/A
Current ratio (mrq)4.36
Book value per share (mrq)-2.41

Cash flow statement

Operating cash flow (ttm)-44.85M
Levered free cash flow (ttm)-35.66M